In a clinical trial (NCT01964924) in patients with TNBC found that eight out of 37 patients in the trametinib arm experienced clinical benefits, highlighting the potential for further studies in larger cohorts to clarify MEK inhibition’s role in BC. Here, MAP2K7 is linked to breast cancer.